Jared Jaffe, DO
Nephrology · Boca Raton, FLNPI 1093709859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 759 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 759 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Amgen$2K
- OPKO Pharmaceuticals, LLC$1K
- Mallinckrodt Hospital Products Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Bayer$885
- plus $9K from 40 others
Across 48 payments — averaging $5153.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$196K
- Merck$41K
- Bayer$10K
What the payments were for
- Consulting fees$7254%
- Food & beverage$17,54394%
- Education$3602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,628 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 22 | $1,003,391 |
| MounjaroTirzepatide | 345 | $436,013 |
| FarxigaDapagliflozin Propanediol | 174 | $239,547 |
| TavneosAvacopan | 12 | $202,133 |
| OzempicSemaglutide | 111 | $160,287 |
| FilspariSparsentan | 13 | $132,635 |
| JardianceEmpagliflozin | 92 | $129,354 |
| RayaldeeCalcifediol | 47 | $101,291 |
| EliquisApixaban | 51 | $73,957 |
| TrulicityDulaglutide | 43 | $56,602 |
| KerendiaFinerenone | 28 | $49,868 |
| LokelmaSodium Zirconium Cyclosilicate | 42 | $45,169 |
| XifaxanRifaximin | 13 | $40,438 |
| EntrestoSacubitril/Valsartan | 23 | $26,028 |
| Repatha SureclickEvolocumab | 35 | $20,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $81 | $1,003,39122 claims |
| Lilly USA, LLCMounjaro, Trulicity | $519 | $492,615388 claims |
| AstraZenecaFarxiga, Lokelma | $3,156 | $284,716216 claims |
| AmgenTavneos | $2,167 | $202,13312 claims |
| Novo NordiskOzempic | $755 | $160,287111 claims |
| Travere Therapeutics, Inc.Filspari | $430 | $132,63513 claims |
| Boehringer IngelheimJardiance | $270 | $129,35492 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $1,334 | $101,29147 claims |
| PfizerEliquis | $87 | $73,95751 claims |
| BayerKerendia | $885 | $49,86828 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $65 | $40,43813 claims |
| NovartisEntresto | $608 | $26,02823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.
Other nephrology in Boca Raton
- Marc RichardsBoca Raton$61K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.